MHRA Grants Marketing Authorisation for Redemplo in Adults With FCS
Arrowhead Pharmaceuticals says the MHRA granted marketing authorisation for Redemplo (plozasiran) to treat familial chylomicronemia syndrome in adults.
Arrowhead Pharmaceuticals says the MHRA granted marketing authorisation for Redemplo (plozasiran) to treat familial chylomicronemia syndrome in adults.